BioInvent International AB Year-end Report January 1 - December 31, ...
BioInvent International AB Year-end Report January 1 - December 31, ...
Source: pr-inside.com
Therapy Acceleration Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Therapy Acceleration Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Therapy Acceleration Program Today - Breaking & Trending Today
BioInvent International AB Year-end Report January 1 - December 31, 2023
LUND, SWEDEN / ACCESSWIRE / February 22, 2024 / BioInvent International (STO:BINV) "2023 was a landmark year for BioInvent with positive clinical readouts from three Phase 1/2 programs. These data, supported by validating partnerships, a strong cash position and solid investor base, set BioInvent up to have a b...
Source: pharmiweb.com
BioInvent to Evaluate BI-1206 in Combination with Rituximab and Calquence ...
BioInvent to Evaluate BI-1206 in Combination with Rituximab and Calquence ...
Source: pr-inside.com
Rgenta Therapeutics Joins The Leukemia & Lymphoma Society Therapy Acceleration Program®
/PRNewswire/ -- Rgenta Therapeutics ("Rgenta" or the "Company") today announced that it was selected by The Leukemia & Lymphoma Society (LLS) as a new Therapy...
Source: prnewswire.com
BioInvent announces 2024 strategic priorities and anticipated milestones
Data from seven different clinical studies expected throughout the year, including combination data for the two lead programs BI-1808 and BI-1206 in H1/mid-2024Well-financed with 1358 SEK million , as...
Source: marketscreener.com